SCHEMBL23748265

SCHEMBL23748265

COC(=O)c1c(F)cccc1COc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.54
PARP15 Q460N3 2/20 0.50
PARP10 Q53GL7 2/20 0.50
PARP14 Q460N5 1/20 0.50
MAPT P10636 1/20 0.48
RAB9A P51151 1/20 0.48
SCN9A Q15858 1/20 0.46
SCN3A Q9NY46 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MRGPRX4 Q96LA9 1/20 0.45
PTGER1 P34995 1/20 0.45
PTGER4 P35408 1/20 0.45
PTGER3 P43115 1/20 0.45
PTGER2 P43116 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
MAPK10 P53779 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721276 0.84 MAOB (0.55) MAOBPARP15PARP10PARP14RAB9A
SCHEMBL18329438 0.81 CA12 (0.50) RAB9AKMT2ABDKRB1
SCHEMBL19497046 0.80 BDKRB1 (0.49) KMT2ABDKRB1
SCHEMBL17166118 0.80 CA12 (0.48) KMT2ABDKRB1
SCHEMBL1444069 0.79 MAOB (0.74) MAOBPARP15PARP10PARP14MAPT
SCHEMBL31123658 0.78 ALDH1A1 (0.60) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL8322933 0.78 CA12 (0.47) KMT2ABDKRB1
SCHEMBL1070351 0.77 CA12 (0.61) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL6832431 0.76 KDM4E (0.61) PARP10RAB9AMEN1KMT2AHSD17B10
SCHEMBL14505835 0.75 MAOB (0.59) MAOBPARP15PARP10PARP14MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed
CN-113195502-A Macrocyclic influenza endonuclease inhibitors 詹森生物制药有限公司 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 MAOB 146/4885PARP15 1998/4885PARP10 3361/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP MAOB 69/4885PARP15 1997/4885PARP10 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.